Oncocyte Corporation (OCX) Actualités

Form D - Notice of Exempt Offering of Securities

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Oncocyte Signs Leading Transplant Centers in US and Germany

GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant...

Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the...

Form DEF 14A - Other definitive proxy statements

PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an illuminating...

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

IRVINE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form EFFECT - Notice of Effectiveness

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results

Interest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land...